Some great insights there and statistically significant findings more importantly.
Skin grafts were applied to 39 patients (84.8%) treated with CCS compared with 28 (54.9%) treated with BTM (P =.006); the remaining wounds healing secondarily.
The rate of skin graft failure was significantly higher in the CCS cohort (n = 9 [23.1%]) compared with the BTM group (n = 1 [3.6%]) (P =.006).
More secondary procedures were required after CCS placement (mean ± standard deviation, 1.9 ± 1.8; range, 0-9) than after BTM (mean, 1.0 ± 0.9; range 0-4) (P =.002).
Less rates of skin grafting required, extremely lower rates of graft failure and less secondary procedures required (P<0.05). This is what you want to see when calculating health economics of a medical device! Cheers for the insights KJC.
- Forums
- ASX - By Stock
- PNV
- The Clinicians Speak
The Clinicians Speak, page-139
-
- There are more pages in this discussion • 905 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
|
|||||
Last
$2.44 |
Change
-0.020(0.81%) |
Mkt cap ! $1.685B |
Open | High | Low | Value | Volume |
$2.44 | $2.48 | $2.41 | $2.454M | 1.003M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 11177 | $2.43 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.46 | 1992 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 65 | 2.440 |
4 | 4900 | 2.430 |
2 | 40661 | 2.420 |
3 | 13000 | 2.410 |
8 | 44738 | 2.400 |
Price($) | Vol. | No. |
---|---|---|
2.460 | 1992 | 1 |
2.470 | 18992 | 2 |
2.480 | 1992 | 1 |
2.490 | 4508 | 2 |
2.500 | 16320 | 3 |
Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
UNT
UNITH LTD
Idan Schmorak, CEO
Idan Schmorak
CEO
Previous Video
Next Video
SPONSORED BY The Market Online